Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
29 July 2022 |
Main ID: |
NCT02692716 |
Date of registration:
|
23/02/2016 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
PIONEER 6 |
Scientific title:
|
A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes |
Date of first enrolment:
|
January 17, 2017 |
Target sample size:
|
3183 |
Recruitment status: |
Completed |
URL:
|
https://clinicaltrials.gov/show/NCT02692716 |
Study type:
|
Interventional |
Study design:
|
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
|
Phase:
|
Phase 3
|
|
Countries of recruitment
|
Algeria
|
Argentina
|
Brazil
|
Canada
|
Denmark
|
Germany
|
India
|
Israel
|
Italy
|
Malaysia
|
Mexico
|
Netherlands
|
Poland
|
Romania
|
South Africa
|
Spain
|
Taiwan
|
Thailand
|
Turkey
|
United Kingdom
|
United States
| | | |
Contacts
|
Name:
|
Global Clinical Registry (GCR, 1452) |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Novo Nordisk A/S |
| | |
Key inclusion & exclusion criteria
|
Health Condition(s) or Problem(s) studied
|
Source(s) of Monetary Support
|
|